Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NUVB News 2 January 2026 - 12 January 2026

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

New York, Jan 12, 2026, 14:44 ET — Regular session underway Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded. (SEC) This is crucial now as Nuvation aims to show it’s more than just a development-stage player and can operate as a commercial drugmaker. The market has little patience for any slip in early prescription numbers, even with plenty of cash on hand. The Eisai
12 January 2026
·····
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

New York, Jan 9, 2026, 14:36 (EST) — Regular session Nuvation Bio Inc (NUVB) shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05. The stock’s pullback follows new sell-side takes on a name that’s been re-rated since shifting into the commercial stage. UBS started coverage at Neutral with a $10 price target. RBC, meanwhile, lifted its target to $9 from $8 and maintained an Outperform rating, calling the stock “speculative risk.” (MarketScreener) UBS analyst Michael Yee said the bigger picture is starting to turn, arguing biotech “fundamentals are now inflecting” as investor confidence
9 January 2026
···
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

NEW YORK, Jan 2, 2026, 2:49 PM ET — Regular session Shares of Nuvation Bio Inc fell about 6.8% to $8.35 in afternoon trading on Friday, after opening at $8.97 and swinging between $9.13 and $8.30. About 3.3 million shares had changed hands. The decline stood out against a softer but steadier biotech tape. The SPDR S&P Biotech ETF was down about 0.7% and iShares Nasdaq Biotechnology ETF slipped about 0.2%, while the S&P 500 ETF was modestly higher and small caps outperformed. The stock’s slide comes as investors recalibrate risk in the first U.S. session of 2026, with strategists
2 January 2026
····

Stock Market Today

Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop